Search -

Displaying 1 - 20 of 225

Sort: Relevancy | Date

News Daily News

Previewing 30-Year ASCVD Risk May Open Door to Earlier Treatment

Yael L. Maxwell

January 21, 2026

News Opinion CV Team Dispatch

January 2026 Dispatch for the CV Team

L.A. McKeown

January 16, 2026

News Daily News

Weight Regained Within 18 Months of Stopping GLP-1 Drugs

Michael O'Riordan

January 08, 2026

News Daily News

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

Michael O'Riordan

December 30, 2025

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

News Opinion CV Team Dispatch

December 2025 Dispatch for the CV Team

L.A. McKeown

December 23, 2025

News Daily News

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Michael O'Riordan

December 18, 2025

News Daily News

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Michael O'Riordan

December 12, 2025

News Daily News

WHO Endorses Treating Obesity in Adults With GLP-1s

Todd Neale

December 01, 2025

News Opinion CV Team Dispatch

October 2025 Dispatch for the CV Team

L.A. McKeown

October 25, 2025

News Daily News

Semaglutide’s CV Effects Only Partially Tied to Weight Loss: SELECT Analysis

Yael L. Maxwell

October 24, 2025

News Daily News

High Aerobic Fitness Linked to Less Chronic Disease in Later Life

Michael O'Riordan

October 10, 2025

News Daily News

Risk Factors Present in Nearly All Patients Who Develop CVD

Michael O'Riordan

October 02, 2025

News Daily News

CVD Still the Leading Cause of Death and Disease Globally

Michael O'Riordan

September 24, 2025

News Daily News

Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s

Michael O'Riordan

September 18, 2025

News Daily News

Half of Patients Stop Semaglutide for Weight Loss by 1 Year

Todd Neale

September 18, 2025

News Daily News

AI-Supported Coaching Shows Promise for Improving Glycemic Control

L.A. McKeown

August 25, 2025

News Daily News

Body Fat Distribution Influences Cardiovascular Age

Todd Neale

August 22, 2025

News Opinion CV Team Dispatch

August 2025 Dispatch for the CV Team

L.A. McKeown

August 22, 2025

News Daily News

Healthcare Expenses Increase After GLP-1 Prescription

L.A. McKeown

August 18, 2025

Advertisement

Previewing 30-Year ASCVD Risk May Open Door to Earlier Treatment

January 2026 Dispatch for the CV Team

Weight Regained Within 18 Months of Stopping GLP-1 Drugs

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

Year in Review: Top Prevention Stories of 2025

December 2025 Dispatch for the CV Team

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

WHO Endorses Treating Obesity in Adults With GLP-1s

October 2025 Dispatch for the CV Team

Semaglutide’s CV Effects Only Partially Tied to Weight Loss: SELECT Analysis

High Aerobic Fitness Linked to Less Chronic Disease in Later Life

Risk Factors Present in Nearly All Patients Who Develop CVD

CVD Still the Leading Cause of Death and Disease Globally

Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s

Half of Patients Stop Semaglutide for Weight Loss by 1 Year

AI-Supported Coaching Shows Promise for Improving Glycemic Control

Body Fat Distribution Influences Cardiovascular Age

August 2025 Dispatch for the CV Team

Healthcare Expenses Increase After GLP-1 Prescription

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content